Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

[1]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[2]  I. Gorelov,et al.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.

[3]  S. Schreiber,et al.  Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis , 2008, Gut.

[4]  G. Houin,et al.  Is Once‐Daily Mesalazine Equivalent to the Currently Used Twice‐Daily Regimen? A Study Performed in 30 Healthy Volunteers , 2007, Journal of clinical pharmacology.

[5]  J. Rhodes,et al.  Ulcerative colitis: diagnosis and management , 2006, BMJ : British Medical Journal.

[6]  R. Cohen.  Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[7]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[8]  O. Paoluzi,et al.  Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study , 2005, Alimentary pharmacology & therapeutics.

[9]  H. V. Gelder.  The Netherlands , 2004, Constitutions of Europe (2 vols.).

[10]  M. J. Shale,et al.  Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[11]  A. Cohen,et al.  Patient nonadherence to medication in inflammatory bowel disease. , 2003 .

[12]  D. Huo,et al.  A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  M. Stolte,et al.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.

[14]  S. Hanauer,et al.  Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis , 2001, American Journal of Gastroenterology.

[15]  T. Hinterleitner,et al.  Mesalazine 4 g Daily Given as Prolonged-Release Granules Twice Daily and Four Times Daily Is at Least as Effective as Prolonged-Release Tablets Four Times Daily in Patients with Ulcerative Colitis , 2001, Inflammatory bowel diseases.

[16]  S. Riley,et al.  Once versus divided daily dosing with delayed‐release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters , 2001, Alimentary pharmacology & therapeutics.

[17]  S. Riley,et al.  Simple method for the determination of 5-aminosalicylic and N-acetyl-5-aminosalicylic acid in rectal tissue biopsies. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[18]  M. Vatn,et al.  Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. , 1997, Scandinavian journal of gastroenterology.

[19]  S. Hanauer,et al.  An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis , 1996, Annals of Internal Medicine.

[20]  P. Fockens,et al.  Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis , 1995 .

[21]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[22]  S. Lo,et al.  Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. , 1991, Annals of internal medicine.

[23]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[24]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[25]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[27]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.